Search
Nitrendipine
go.drugbank.com/drugs/DB01054ApprovedWithdrawnNitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...
Products: NITRENDIPINO DE 10 MG, NITRENDIPINO DE 20 MGAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalpresence of ANCAs in the serum. … [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving … Tyenne is the first tocilizumab biosimilar approved in both intravenous and subcutaneous formulations and is authorized to treat several inflammatory conditions, including rheumatoid arthritis and juvenile
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide bridges.
Copper Cu-64
go.drugbank.com/drugs/DB13980ApprovedCopper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linkerVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational[L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed … [L64062,L64063] The approval came on the therapy's third submission, after two prior complete response letters.[L64063]
Teriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalIt is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Nebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigational[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. … Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.
Mixtures: NEBIVOLOLO E IDROCLOROTIAZIDE MYLAN PHARMA, NEBIVOLOLO E IDROCLOROTIAZIDE MYLAN PHARMAProducts: NEBIVOLOLO E IDROCLOROTIAZIDE ACCORDForasartan
go.drugbank.com/drugs/DB01342ExperimentalForasartan competes with angiotensin II for binding at the AT1 receptor subtype. … Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension.
Categories: Agents Acting on the Renin-Angiotensin System